Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
Open Access
- 1 January 2021
- journal article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 1 (1)
- https://doi.org/10.17925/ee.2021.1.1.12
Abstract
The prevalence of diabetes type 1 (T1D) and type 2 (T2D) is increasing worldwide; the number of people with diabetes was 463 million in 2019, but it isKeywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 54 references indexed in Scilit:
- Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2Diabetes Care, 2019
- Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration studyDiabetologia, 2018
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE TrialsDiabetes Care, 2018
- SGLT inhibitor adjunct therapy in type 1 diabetesDiabetologia, 2018
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled TrialDiabetes Care, 2018
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 DiabetesThe New England Journal of Medicine, 2017
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialThe Lancet Diabetes & Endocrinology, 2017
- Incidence of Type 1 Diabetes in Sweden Among Individuals Aged 0–34 Years, 1983–2007Diabetes Care, 2011
- Temporal patterns in overweight and obesity in Type 1 diabetesDiabetic Medicine, 2010
- Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood PressureJAMA, 1998